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Summary Malignant tumours contain normal cells, descendants of transformed cells, and conceivably also
initiated cells which have taken some but not all of the steps toward malignancy, and hybrid cells. Tumours
are propagated by multiplication of clonogenic cells, which are a subclass of the descendants of transformed
cells. The clonogenic cells of a tumour may differ in respect of morphology, karyotype, metastatic capacity,
sensitivity to cytotoxic drugs, expression of cell surface antigens and hormone receptors, immunogenicity,
sensitivity to the immune reaction of the host, and other properties. Evidence (disputed by some) suggests that
selection of particular subpopulations plays a role in tumour metastasis and recurrence. Heterogeneity may be
due to pleoclonal origin, generation of phenotypic diversity within a clone, or spontaneous hybridization and
chromosome loss. The possibility of interaction between different subpopulations must be taken into account
in discussing tumour cell population kinetics. Heterogeneity also has important therapeutic implications and
may help to explain the failure of some therapeutic regimes and the success of others.
A malignant tumour what biologists are apt to
call, redundantly, a solid malignant tumour-is not
just a collection of neoplastic cells but a complex
structure whose cell population includes normal
cells derived from normal progenitors as well as the
descendants of one or more transformed cells. It
may conceivably also include cells which have taken
one or more, but not all, of the steps on the way to
malignancy, which I shall refer to as initiated cells
(or part way cells), and hybrid cells, formed by the
fusion of two cells of the same or different kinds.
The normal cells derived from normal
progenitors include leucocytes of various kinds,
macrophages, fibroblasts and endothelial cells. Their
presence and behaviour in tumours are of great
interest but I shall not discuss them in this review
except to point out that methods of analysis which
fail to detect these cells may also fail to detect
particular subpopulations of malignant cells.
The descendants of transformed cells include
proliferating cells in various stages of the cell cycle,
so called Go cells which have stopped cycling
temporarily but may later re-enter the cycle, and
end state cells which are incapable of further
division. Proliferating cells from which a tumour
may be propagated in the autochthonous or
another host, or in tissue culture, I shall refer to as
clonogenic cells. I shall avoid using the, to me,
fuzzy term tumour stem cell. If this is used to
denote a clonogenic cell it is redundant; if used as a
restricted class of clonogenic cell it is unhelpful
unless this class is clearly defined. If, as sometimes
happens, it is used to denote those cells of a
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tumour which happen to possess the modal number
of chromosomes, it is misleading.
An important question is whether the
descendants of transformed cells can lose their
malignant characteristics but continue to proliferate.
We know from studies by Mintz and her colleagues
(Mintz & Illmensee, 1975; Mintz, 1978) of mice
produced in foster mothers from blastocysts injected
with one or more cells of a teratocarcinoma that
had been induced and maintained by serial
transplantation in a different strain, that a single
teratocarcinoma cell can, under these conditions,
give rise to the whole gamut of normal somatic
tissues and also to fully functioning spermatozoa.
But can the cells of this and other tumours give rise
to proliferating non-malignant cells in the
autochthonous host? I heard this question asked by
Ralston Paterson 35 years ago when discussing the
source of the new epithelium in a patient whose
large ulcerating squamous cell carcinoma had
healed following radiotherapy. We are still awaiting
a definite answer, but with the markers now
available it should be possible to obtain this, at
least in respect of mouse tumours.
Heterogeneity of clonogenic cells
The main theme of this review is the extent to
which the clonogenic cells in malignant solid
tumours and other neoplasms are phenotypically
heterogeneous.
It has long been recognized that many tumours
undergo what Foulds (1969) called progression. This
has been attributed by Nowell (1976) and others to
the stepwise emergence and selection of variant
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cells, and it has been widely assumed that when a
new population emerges it will outgrow, and soon
completely replace, the original population, as
would be the case if both populations grew
independently and exponentially at constant but
different rates. There is, however, abundant evidence
to show that this simple model is invalid, and that
the proliferating cells of a primary malignant
tumour at a particular time may be markedly
heterogeneous in respect of such diverse properties
as karyotype (Dexter et al., 1978), metastatic
capacity as judged either by the development of
spontaneous metastases (Fidler & Kripke, 1977;
Kripke et al., 1978) or by lung colony formation
after i.v. injection of tumour cells (Fidler & Kripke,
1971; Kripke et al., 1978; Suzuki et al., 1978; Fidler
et al., 1981), the presence of hormone receptors
(Sluyser & van Nie, 1974), sensitivity to cytotoxic
drugs (Barranco et al., 1972, 1973; Hakansson &
Trope, 1974; Trope, 1975; Houghton et al., 1976;
Donelli et al., 1977), expression of surface antigens
(Prehn, 1970; Byers & Johnson, 1977; Killion 1978;
Miller & Heppner, 1979; Olsson & Ebbesen, 1979),
immunogenicity and/or responsiveness to the
immune reaction of the host (Prehn, 1970; Miller &
Heppner, 1979; Miller et al., 1980), tumorigenic
capacity on transplantation (Schmitt & Daynes,
1981; Woodruff et al., 1982), and morphology and
growth rate in tissue culture (Dexter et al., 1978).
The role of selection of particular subpopulations in
tumour metastasis, and in the recurrence of
tumours after incomplete ablation, is controversial.
Alexander (1982), in the light of experiments in
which pulmonary metastases from transplanted rat
fibrosarcomas showed no greater metastatic
capacity when retransplanted than transplants of
the primary tumour, concluded that "the fate of
cells shed from the tumour is determined by
anatomical and host factors, and metastasis appears
to be a stochastic rather than a selective process".
But failure to find evidence of selection in a
particular experimental model does not justify such
a far reaching conclusion, and others have reported
the existence of phenotypic differences between cells
of a primary tumour and those of a local recurrence
(Pimm & Baldwin, 1977) or metastasis (Baylin et al.,
1978; Fogel et al., 1979), and between different
metastases of the same tumour (Albino et al., 1981).
Such differences are not surprising when one
considers the magnitude of the environmental
change to which a cell must adapt when it is
transported to a new site or caught up in the local
inflammatory reaction which follows attempted
ablation, by whatever means, of a primary tumour.
Much of this work has been done with animal
tumours, including mouse fibrosarcomas, mammary
carcinomas, leukaemias and melanomas, and the
Lewis lung tumour, and rat fibrosarcomas, but
some relates to human tumours. Here are some
examples:
1. Barranco et al. (1972, 1973) reported that 4 cell
lines which had been isolated from the same
human malignant melanoma differed in their
sensitivity to 1,3-bis-(2-chlorothyl)-1 nitrosourea
and bleomycin. The lines had, however, been
maintained in vitro for 5 years, so the
significance of their observations is difficult to
assess.
2. McGee et al. (1982) have reported that Ca
antigen (Ashall et al., 1982) may be detected in
some areas of a carcinoma but not in others
even where the cells are obviously malignant by
morphological criteria. This raises the possibility
that the cells of the tumour differ in the extent to
which they express Ca, either on the cell
membrane or in the cytoplasm.
3. Baylin et al., (1978), using autopsy material from
4 patients with small cell carcinoma of the lung,
compared the amounts of histaminase, L-Dopa
decarboxylase and calcitonin in the primary
tumour and its metastases. They found that the
levels of these markers were low or absent in
hepatic metastases but high in the primary
tumours and in mediastinal metastases. They
reported also that histochemical studies showed
that cells of the primary tumour differed in
respect of their histaminase content.
4. Albino et al. (1981) reported that cell lines
established from 6 separate melanoma
metastases in the same patient differed in respect
of one or more of the following features:
morphology, pigmentation, expression of HLA-
DR antigens, and expression of a tumour-specific
melanoma antigen which they called Mel-1.
5. Differences in the clinical behaviour of different
metastases from the same primary tumour,
though as yet largely unexplained, also strongly
suggest phenotypic diversity. In patients with
multiple cutaneous metastases of malignant
melanoma, for example, as Bodenham (1968)
first observed, some nodules may regress
completely while new ones are appearing in their
vicinity and the total number of nodules is
increasing. It is encouraging that a discovery of
such profound biological significance was made
with an ordinary camera and a few rolls of
black and white film; it is astonishing and
disturbing that it has attracted so little attention
from tumour biologists!
The origins of heterogeneity
How can we account for heterogeneity in tumour
cell populations? There would seem to be three
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1. The tumour develops from more than one
transformed cell (pleoclonal origin).
2. Phenotypic differences are generated within a
clone of transformed cells either by mutation or
by some form of heritable epigenetic change.
3. Spontaneous hybridization occurs between
transformed cells, or between a transformed cell
and an initiated or normal cell, and this is
followed by loss of chromosomes from the
hybrid cell.
Pleoclonality
Two types of marker have been used to assess
whether or not a tumour is monoclonal: karyotypic
abnormalities and gene products of various kinds.
Karyotypic abnormalities are found in a great
variety of tumours but are of particular interest in
the present context as evidence that certain
leukaemias are monoclonal. Despite the
persuasiveness of this evidence it is worth pointing
out that the presence of a particular abnormality in
virtually all the cells examined does not exclude the
possibility that the neoplasm may have arisen from
a number of cells which all carried the marker in
question before they were transformed. This
theoretical possibility seems a little less remote in
the light of recent evidence that, in mice,
haemopoiesis after bleeding is achieved by the
expansion in succession of clones derived from a
small number of "stem cells for stem cells" (Burton
et al., 1982).
The gene products studied may be located on the
cell surface or within the cell, or externally secreted.
In the special case of immunoglobulin-producing
tumours the characteristics of the immunoglobulin
are normally used.
With human solid tumours which do not secrete
immunoglobulin many studies of clonality have
been based on the mosaicism which exists in the
normal tissues of women who are heterozygous for
the two forms of the enzyme glucose-6-phosphate
dehydrogenase (G-6-PD). This mosaicism results
from the inactivation of one X-chromosome in all
somatic cells, and should not exist in a monoclonal
population. As a result of the work of Fialkow and
others with this marker (Fialkow, 1976), it has
become widely accepted that most, though not all,
human solid tumours are monoclonal in origin, but
interpretation of the data is not as straightfoward
as it appears. On the one hand, a pleoclonal
tumour may appear to be monoclonal because it
has arisen from a "patch" of transformed cells of
the same type or because it contains subpopulations
too small to be detected; on the other hand, a
monoclonal tumour may appear to be polyclonal
because of the presence of non-neoplastic cells in
the population tested. Moreover, a tumour which is
monoclonal when tested may have been polyclonal
at an earlier stage in its life history.
In the hope of resolving these doubts, people
have looked for animal models to study.
Isoenzymes of G6PD have been identified in Mus
Caroli but unfortunately not in Mus musculus. A
few years ago, however, an electrophoetic variant
(A) of the X-coded enzyme phosphoglycerate
kinase-l (PGK-1) which differs from the B form
found in common laboratory strains of Mus
musculus, was found in a feral mouse of this species.
Following this discovery, Reddy & Fialkow (1979)
reported that fibrosarcomas induced chemically in
female hybrids of feral and laboratory-bred mice
expressed both forms of the enzyme and were
therefore polyclonal, but the conclusion that both
isoenzymes were produced by neoplastic cells was
based solely on morphological evidence. To
overcome this limitation, my colleagues and I
(Woodruff et al., 1982) have induced fibrosarcomas
in genetically standardized female mice expressing
both alloenzymes (AB mice), obtained by crossing
normal CBA mice which express only the B form of
the enzyme (B mice) with CBA backcross mice
expressing only the A form (A mice). Enzyme assays
were performed not only on freshly removed
primary tumours but also on tumours, and clones
derived from them, which had been maintained in
tissue culture or transplanted to histocompatible A
mice or B mice.
Cell suspensions from whole tumours often
yielded both alloenzymes: suspension from tissue
cultures of primary tumours did so less often. We
attribute this difference to the elimination of
leucocytes, which do not adhere to tissue culture
flasks and were discarded, and macrophages, which
adhere so strongly that they were left behind when
the tumour cells were harvested. With many
tumours the A/B ratio fluctuated markedly in the
course of tissue culture. In some cases a component
which was predominant initially later disappeared
completely; in others a component which was not
detected initially appeared later and eventually
predominated. A clones and B clones were isolated
from some tumours and were proved to be
tumorigenic by transplantation. Although whole
tumour suspensions regularly gave rise to tumours
in normal mice many individual clones failed to do
so; they did grow, however, in thymectomized,
irradiated mice, and, after passage in such mice,
usually grew in normal mice. This suggests that
cells with a high capacity for survival are selected
when a pleoclonal population is transplanted or,
alternatively, that some clones require the
cooperation of others to survive. Clones which
expressed both A and B were isolated from one
tumour. The significance of this observation is
discussed below.592 M.F.A. WOODRUFF
Taken as a whole the results highlight the
problems involved in assessing the clonal status of
tumours with X-linked markers, and raise doubts
about the validity of some of the conclusions based
on G-6 PD studies of human tumours.
The generation ofdiversity within clones
It has been reported that isolated tumour clones
soon become heterogeneous in respect of many of
the properties listed earlier when they are
transplanted or maintained in tissue culture (Fidler
& Hart, 1982). This has been reported with various
tumours; the one which has been most widely used
is the B16 mouse melanoma, and the property
which has been most studied is the capacity of
tumour cells to produce disseminated tumour foci
after i.v. injection. In experiments with a murine
lymphoma, however, Chow & Greenberg (1980)
found that whereas heterogeneity in respect of one
particular marker susceptibility to killing by
naturally occurring cytotoxic antibodies developed
during a single passage in vivo, it did not do so in
vitro, and they concluded, that host factors may
contribute in some way to the generation of
diversity.
In contrast to the instability of cloned
populations, the composition of the original
heterogeneous uncloned population may remain
remarkably constant under similar conditions. Poste
et al. (1981), who first reported this, suggested that
in polyclonal populations the various
subpopulations interact in such a way as to
stabilize their relative proportions within the
population as a whole.
Spontaneous hybridization
As mentioned previously, in our experiments with
fibrosarcomas induced in mice heterozygous for the
two forms of PGK-1, numerous "clones" which
expressed both A and B alloenzymes were
isolated from one tumour. After recloning at extreme
dilution (on average 0.3 clonogenic cells per well)
and again after passage in mice, 50 reclones still
expressed both A and B, 6 expressed B only, and
none expressed A only. It seems clear that our
"clones" were indeed true clones and not mixtures
of A cells and B cells. It seems most likely that they
arose by spontaneous hybridization of cells of
different enzyme phenotypes; it is just possible that
they arose from cells in which chromosome
replication had occurred without cell division and a
previously inactive X-chromosome had become
reactivated. We attribute the loss of the A
component in some cases to selective chromosomal
loss. The cells of the AB clones were markedly
polyploid. Cells from uncloned tumours and clones
expressing only one enzyme phenotype were,
however, usually also polyploid, and we are
presently engaged in a comparative study of the
karyotypes of these various categories of cell.
Some years ago Wiener et al. (1972), using the T6
translocation as marker, obtained evidence of
spontaneous fusion of transplanted murine tumour
cells and host cells. Subsequently, Lala et al. (1980)
have studied the time course of fusion between cells
of the Ehrlich ascites carcinoma and host cells, and
of subsequent chromosome loss. Very recently,
Marshall et al. (1982), using both the T6
translocation and the isoenzymes of phosphoglucose
isomerase as markers, have obtained evidence of
fusion in vitro of neoplastic and host cells from a
transplanted plutonium-induced murine osteogenic
sarcoma. In our experiments evidence of
hybridization was obtained in tumours which had
not been transplanted. It is uncertain whether
hybridization occurred in the primary tumour or
during subsequent manipulations in tissue culture,
but we are setting up experiments with another
enzyme marker which we hope will distinguish
between these possibilities.
Biological and clinical significance of tumour cell
heterogeneity
The existence of cellular heterogeneity in tumours
adds a new dimension to tumour cell population
kinetics, and has important implications for our
understanding of the natural history of tumours
and their response to treatment.
Tumour cell population kinetics
Hitherto, it has been customary to treat the tumour
cell population as if it consisted of cells differing
only in respect of their anatomical location and
their position in the cell cycle. It now becomes
necessary to take into account the possibility of
interactions of either an antagonistic or a
mutualistic kind between subpopulations of cells
with different phenotypic characteristics, as well as
interactions between neoplastic cells and the host
environment.
The existence of different subpopulations
increases the chance that cells with a high
probability of survival will be selected when
environmental conditions change. It may thus
facilitate metastasis (Poste & Fidler, 1980) and local
recurrence of a tumour, and may help to explain
the rapid development of metastases from cells
which have remained dormant long after successful
ablation of the primary tumour (for review see
Woodruff, 1981).
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in interactions between tumour cell subpopulations,
but it is possible to make some plausible
conjectures.
1. Subpopulations may compete for essential
nutrients. Conversely, a metabolic defect in one
subpopulation, whether innate or resulting from
the administration of an antimetabolite drug,
may conceivably be compensated for, to a
greater or lesser extent, by the metabolic activity
of other subpopulations.
2. It has been suggested by Sporn & Todaro (1980)
that tumour cells are stimulated by polypeptides
which they themselves produce. It seems possible
that these substances, which Sporn and Todaro
term autocrine transforming growth factors, may
reach and stimulate other cells; i.e. their effect
may be paracrine as well as autocrine.
Conversely, it is conceivable that some
substances produced by one subpopulation may
inhibit the growth of cells of another
subpopulation. Studies of the behaviour of clonal
mixtures in vitro and in vivo should confirm or
refute this hypothesis.
3. As already mentioned, spontaneous
hybridization may occur between tumour cells,
and also between tumour cells and initiated or
normal cells.
Therapeutic implications
The therapeutic objective in cancer is to destroy the
tumour completely without causing unacceptable
damage to the normal tissues of the host. If a
tumour is localized and does not involve any vital
structure, this objective may be achieved by local
treatment in the form of surgical excision or
radiotherapy. When, as often happens, this
condition is not fulfilled, successful treatment
depends on exploiting differences of various kinds
between normal and neoplastic cells. This becomes
more difficult to achieve when the neoplastic cell
population is itself heterogeneous, for our attack
can no longer be concentrated on a single target
but must encompass multiple targets. The
remarkable achievements of multiple drug
chemotherapy can no doubt be attributed partly to
the fact that the same target is attacked on more
than one front; it may, however, also reflect
differences in the sensitivity of different
subpopulations of cells to particular agents.
The capacity of tumour cell populations to
diversify may however elude even "broad spectrum"
therapy. This may conceivably explain why
adjuvant chemotherapy has so far met with such
limited success in preventing the development of
metastases after removal of a primary tumour.
If, as I believe, there is still much to be learned
about cancer at the cellular level, it seems likely
that one area in which important advances will be
made will be made will be the study of cellular
heterogeneity in tumours.
We have, slowly, come to accept the notion that
cancer is not one disease but many. We must now
face the possibility that a single patient with cancer
may have many diseases. Such a reappraisal may be
agonizing, but without pain there can be no
progress.
I am indebted to the Medical Research Council for a
Project Grant, and to Professor H.J. Evans for the
privilege of working in his unit. I also thank Dr. M. Steel
for helpful comments on the manuscript.
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